Immunovant, Inc.

As of October 31, 2025, Immunovant, Inc. shows a mildly bullish trend driven by weekly indicators, despite mixed signals from monthly metrics and a mildly bearish daily moving average, with recent returns outperforming the S&P 500 over the past week and month.

As of October 31, 2025, Immunovant, Inc. shows a mildly bullish trend with positive signals from Bollinger Bands and Dow Theory, despite mixed MACD indicators and bearish moving averages, while outperforming the S&P 500 recently but lagging in year-to-date returns.

As of October 31, 2025, Immunovant, Inc. shows a mildly bullish trend driven by weekly MACD and Bollinger Bands, despite bearish monthly indicators and underperformance in the long term.

As of September 26, 2025, Immunovant, Inc. has shifted to a mildly bearish trend, influenced by daily moving averages and KST indicators, despite a mildly bullish weekly MACD, while underperforming the S&P 500 with year-to-date and annual returns of -34.48% and -42.67%, respectively.

As of September 26, 2025, Immunovant, Inc. shows a mildly bearish trend with mixed signals across time frames, underperforming the S&P 500 year-to-date and over the past year, but significantly outperforming it over the past three years.

As of September 26, 2025, Immunovant, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed year-to-date and over the past year.

As of August 27, 2025, Immunovant, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with year-to-date and one-year returns of -37.83% and -46.71%, respectively.

As of May 29, 2025, the market trend is mildly bearish, with daily moving averages and weekly Dow Theory indicating bearishness, while mixed signals from MACD, Bollinger Bands, and KST suggest a cautious approach.

As of March 2022, the management team of Immunovant, Inc. includes Dr. Frank Torti (Chairman), Dr. Peter Salzmann (CEO), Dr. Eric Venker, and several independent directors: Andrew Fromkin, Douglas Hughes, George Migausky, and Atul Pande. They oversee the company's strategic direction and operations.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases, with a market cap of approximately $2.62 billion and a recent net profit of -$106 million. The company has no dividend yield and is currently loss-making.

As of Jun 18, Immunovant, Inc. has a market capitalization of $2.62 billion, with net sales of $0.00 million and a net profit of -$413.84 million over the last four quarters. The company reported shareholder's funds of $707.45 million and total assets of $777.32 million as of Mar 25.